Monte Rosa Therapeutics, Inc. GLUE R2K

Healthcare · Biotechnology · United States

https://www.monterosatx.com

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Market & Price

Market Cap

$1.67B

Current Price

$19.71

High / Low (52W)

$25.31 / $4.18

Beta

1.62

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$6.19

Price to Book

3.18

P/S

38.77

EV/EBITDA

-7.42

Dividend Yield

Profitability & Returns

ROCE

-14.10%

ROE

-32.62%

ROA

-16.41%

Profit Margin

0.00%

Op Margin

EPS (Latest Qtr)

$-0.45

EPS (TTM)

$-1.48

Balance Sheet & Liquidity

Debt/Equity

0.07

Quick Ratio

9.44

Current Ratio

9.54

Debt

$39.06M

Total Assets

$448.66M

Current Assets

$393.19M

Working Capital

$328.97M

Ownership

Promoter Holding

0.59%

Chg in Prom Hold

FII / Inst Holding

113.10%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.04B

Total Revenue (TTM)

$42.95M

EBITDA

$-139.94M

Free Cash Flow

$-77.16M

Operating Cash Flow

$-14.68M

Shares Outstanding

84.48M

Gross Margin

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

21.47%

Revenue (YoY)

-95.00%

Earnings (YoY)

PROS

Profit CAGR of 21.5% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GLUE Monte Rosa Therapeutics, Inc. R2K	19.71	-	$1.67B	-	-14.10%	-32.62%	-	21.47%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	0	0	0	1.06M	4.70M	9.22M	84.93M	23.19M	12.77M	2.78M	4.21M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40.89M	38.75M	45.74M	52.50M	54.24M
Operating Income	-	-5.40M	-6.39M	-11.50M	-18.12M	-19.87M	-24.30M	-27.23M	-28.36M	-34.26M	-37.22M	-36.97M	-34.95M	-32.64M	-26.53M	44.04M	-15.55M	-32.98M	-49.72M	-50.03M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46.08M	-13.43M	-30.88M	-47.63M	-48.01M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	47.71M	-11.10M	-30.26M	-46.08M	-44.45M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	822.00K	1.20M	-3.18M	59.00K	52.00K
Net Income	-4.30M	-5.36M	-6.56M	-12.28M	-18.41M	-19.84M	-23.93M	-26.47M	-27.32M	-32.04M	-35.18M	-34.88M	-31.97M	-30.31M	-23.86M	46.88M	-12.29M	-27.08M	-46.13M	-44.50M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.57	-0.20	-0.44	-0.70	-0.45
R&D Expense	-	4.86M	5.47M	9.27M	14.64M	15.12M	17.91M	20.94M	21.34M	26.75M	29.08M	28.31M	27.03M	28.05M	27.62M	32.19M	30.65M	36.68M	-	44.07M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	0	0	75.62M	123.67M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	-	-	112.38M	143.31M	156.73M	177.88M
Operating Income	-28.01M	-	-112.38M	-143.31M	-81.11M	-54.21M
EBITDA	-	-	-108.64M	-137.09M	-72.99M	-45.85M
Interest Expense	-	-	-	-	-	-
Pretax Income	-	-	-108.50M	-135.01M	-70.13M	-39.72M
Tax Provision	-	-	0	338.00K	2.57M	-1.10M
Net Income	-35.88M	-	-108.50M	-135.35M	-72.70M	-38.63M
Diluted EPS	-	-2.96	-2.30	-2.63	-1.18	-
R&D Expense	24.00M	57.16M	85.06M	111.27M	121.56M	141.50M

Compounded Sales Growth

5 Years:	-
1 Year:	-95.00%

Compounded Profit Growth

5 Years:	21.47%
1 Year:	-

Stock Price Performance

1 Year:	+371.53%
6 Months:	+23.03%
3 Months:	+11.04%
1 Month:	+5.29%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	49.38M	-	342.39M	303.75M	438.73M	448.66M
Current Assets	-	-	275.89M	236.21M	377.44M	393.19M
Cash & Equivalents	41.70M	-	54.91M	128.10M	224.25M	129.88M
Inventory	-	-	-	-	-	-
Receivables	-	-	7.66M	505.00K	173.00K	11.60M
Total Liabilities	30.34M	-	70.98M	124.50M	215.80M	215.60M
Current Liabilities	29.27M	-	25.57M	46.59M	156.95M	64.21M
Long Term Debt	-	-	-	-	-	-
Total Debt	-	-	47.00M	46.04M	42.72M	39.19M
Total Equity	-48.73M	-	271.41M	179.25M	222.94M	233.06M
Shares Outstanding	-	-	49.45M	50.14M	61.51M	65.54M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-23.05M	-	-92.47M	-43.80M	42.00M	-22.80M
Investing Cash Flow	-3.39M	-	-219.22M	88.80M	-44.45M	-101.83M
Financing Cash Flow	60.06M	-	20.47M	27.49M	98.89M	30.35M
Capital Expenditure	-3.39M	-	-12.91M	-19.04M	-3.99M	-4.70M
Free Cash Flow	-26.44M	-	-105.38M	-62.84M	38.01M	-27.50M
Net Change in Cash	-	-	-291.22M	72.49M	96.44M	-94.28M
Dividends Paid	-	0	0	0	0	0

Ratios (Annual)

Figures in %.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-107.3%	-43.8%
Net Margin %	-	-	-	-	-96.1%	-31.2%
ROE %	73.6%	-	-40.0%	-75.5%	-32.6%	-16.6%
ROCE %	-139.3%	-	-35.5%	-55.7%	-28.8%	-14.1%

Shareholding Pattern

Insiders

0.59%

Institutions

113.10%

Public Float

113.77%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	NEA Management Company, LLC	9.11%	7.69M	$151.62M
2	Price (T.Rowe) Associates Inc	7.95%	6.72M	$132.45M
3	Blackrock Inc.	6.67%	5.64M	$111.12M
4	TCG Crossover Management, LLC	5.47%	4.62M	$91.10M
5	BVF Inc.	5.28%	4.46M	$87.92M
6	Baker Bros. Advisors, LP	5.14%	4.35M	$85.65M
7	Suvretta Capital Management, LLC	5.00%	4.23M	$83.31M
8	Vestal Point Capital, LP	4.27%	3.60M	$71.02M
9	State Street Corporation	3.97%	3.35M	$66.11M
10	Braidwell LP	3.80%	3.21M	$63.20M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GLUE

No recent headlines available.

GLUE · Healthcare